TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7556858

Group type: COMPARATOR
Intervention: 600 mg ibuprofen preoperatively
Number of subjects: 619

Group type: COMPARATOR
Intervention: Buffered 1% lidocaine
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Waiting times of 0, 3 and 10-20 min between injection and procedure
Number of subjects: 619

Group type: COMPARATOR
Intervention: Slow injection of local anesthetic into one side of the cervix
Number of subjects: 619
Study: 2300411

Group type: EXPERIMENTAL
Intervention: Acellular vaccine
Number of subjects: 201

Group type: COMPARATOR
Intervention: Whole cell vaccine
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Booster dose of acellular vaccine
Number of subjects: 201
Study: 383273

Group type: EXPERIMENTAL
Intervention: 9 cycles of CVP (cyclophosphamide + vincristine + prednisolone)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 55
Study: 30465917

Group type: EXPERIMENTAL
Intervention: Calcium carbonate supplementation (1500 mg Ca/d)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 28107846

Group type: EXPERIMENTAL
Intervention: Breathing patterns during the active phase of the first stage of labor
Number of subjects: 140

Group type: COMPARATOR
Intervention: Routine care service (Control)
Number of subjects: 140
Study: 25529474

Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal D(®)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acuvue Oasys for Presbyopia
Number of subjects: 19

Group type: COMPARATOR
Intervention: Naked eye
Number of subjects: 19
Study: 23498899

Group type: EXPERIMENTAL
Intervention: Instant coffee containing 3 mg of caffeine/kg body weight
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Instant coffee containing 6 mg of caffeine/kg body weight
Number of subjects: 33

Group type: COMPARATOR
Intervention: Water
Number of subjects: 33
Study: 21210182

Group type: EXPERIMENTAL
Intervention: GDT with 2-back working memory task (high executive load)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GDT with 1-back working memory task (low executive load)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GDT without secondary task
Number of subjects: 0
Study: 19124484

Group type: EXPERIMENTAL
Intervention: Coexpression of alpha6beta4 integrin and Net1
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Coexpression of alpha6beta4 integrin and Net1 in hormone receptor-positive tumors
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Lymphovascular invasion
Number of subjects: 94
Study: 17475318

Group type: EXPERIMENTAL
Intervention: Direct mailing
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Newspaper advertisements
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Other sources (e.g., word of mouth)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Posters and brochures
Number of subjects: 70
Study: 15127079

Group type: EXPERIMENTAL
Intervention: Mifepristone (RU-486) 600 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11445772

Group type: EXPERIMENTAL
Intervention: Progressive contractions lasting 4 s
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ballistic contractions lasting about 1 s
Number of subjects: 16
Study: 9593071

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7838620

Group type: EXPERIMENTAL
Intervention: Benzyl-benzoate foam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (absolute control)
Number of subjects: 24
Study: 3044868

Group type: EXPERIMENTAL
Intervention: 650 mg aspirin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 250 mg mefenamic acid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of 650 mg aspirin and 250 mg mefenamic acid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30572524

Group type: EXPERIMENTAL
Intervention: TMBCZG high-dose group (3 tablets, twice per day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: TMBCZG middle-dose group (2 tablets and placebo 1 tablet twice per day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: TMBCZG low-dose group (1 tablet and placebo 2 tablets, twice per day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo group (placebo 3 tablets, twice per day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 160
Study: 28388932

Group type: EXPERIMENTAL
Intervention: Sodium benzoate (1000 mg, 500 mg twice daily for 12 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 26035291

Group type: EXPERIMENTAL
Intervention: o‐CEE (0.45 mg/d) plus m‐P (200 mg/d for the first 12 d of each month)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: t‐E2 (50 μg/d) plus m‐P (200 mg/d for the first 12 d of each month)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Placebo pills and patches
Number of subjects: 693
Study: 24282343

Group type: EXPERIMENTAL
Intervention: Bridging treatments (transarterial chemoembolization, radiofrequency ablation, surgical resection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bridging treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Downstaging treatments
Number of subjects: 0
Study: 20883846

Group type: EXPERIMENTAL
Intervention: Warm Water Infusion (WWI)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 230
Study: 18413618

Group type: EXPERIMENTAL
Intervention: 90-microL testosterone metered-dose transdermal spray
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: 56-microL testosterone metered-dose transdermal spray
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Two 90-microL testosterone metered-dose transdermal sprays
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 15899748

Group type: EXPERIMENTAL
Intervention: 20-minute self-administered intervention with normative feedback and goal setting
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control condition (reading a general AIDS information pamphlet)
Number of subjects: 155
Study: 12091193

Group type: EXPERIMENTAL
Intervention: Low-dose lithium (serum level=0.4-0.6 meq/liter)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard-dose lithium (serum level=0.8-1.0 meq/liter)
Number of subjects: 94
Study: 10343191

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate 1,200 mg (arm I)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate 600 mg (arm II)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (both arms)
Number of subjects: 80
Study: 8745317

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha (rIFN) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated carriers undergoing spontaneous HBeAb seroconversion
Number of subjects: 30
Study: 2028771

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 404

Group type: COMPARATOR
Intervention: Methylcellulose
Number of subjects: 404
Study: 6119764

Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl) for 2 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sulfasalazine (Salazopyrin) for 2 weeks
Number of subjects: 9
Study: 30879128

Group type: COMPARATOR
Intervention: nPRP
Number of subjects: 30

Group type: COMPARATOR
Intervention: nPRP + ASC
Number of subjects: 30
Study: 30712963

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy after complete or optimal primary surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatinum at interval surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 29037633

Group type: EXPERIMENTAL
Intervention: Pilates sessions, twice a week for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (static stretching)
Number of subjects: 32
Study: 25802890

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 105

Group type: COMPARATOR
Intervention: proseal
Number of subjects: 105

Group type: COMPARATOR
Intervention: supreme
Number of subjects: 105
Study: 24025001

Group type: EXPERIMENTAL
Intervention: 10 mg of morphine (10-cc volume)
Number of subjects: 82

Group type: COMPARATOR
Intervention: 10 cc of .5% bupivacaine
Number of subjects: 82
Study: 21868190

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (10 mL of 1% ropivacaine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subacromial infiltration of local anesthesia (20 mL of 1% ropivacaine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 19152449

Group type: EXPERIMENTAL
Intervention: CAPIRI
Number of subjects: 46

Group type: COMPARATOR
Intervention: CAPIRI-Bev
Number of subjects: 46
Study: 17356255

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 15482085

Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard-care practitioner advice
Number of subjects: 63
Study: 11553192

Group type: EXPERIMENTAL
Intervention: Depression symptoms in female patients with Type 2 diabetes
Number of subjects: 1611

Group type: EXPERIMENTAL
Intervention: Depression symptoms in male patients with Type 2 diabetes
Number of subjects: 1611

Group type: EXPERIMENTAL
Intervention: Depression symptoms in female patients (general)
Number of subjects: 1611

Group type: EXPERIMENTAL
Intervention: Depression symptoms in male patients (general)
Number of subjects: 1611
Study: 10875887

Group type: EXPERIMENTAL
Intervention: rHCG (250 microg)
Number of subjects: 190

Group type: COMPARATOR
Intervention: uHCG (5000 IU)
Number of subjects: 190
Study: 9286801

Group type: EXPERIMENTAL
Intervention: Noncontact Ho:YAG LTK (1 or 2 symmetrical octagonal rings of 8 spots/ring, 10 pulses of laser light at 5 Hz, variable pulse energy 208‐242 mJ)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Noncontact Ho:YAG LTK (1 ring treatment)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Noncontact Ho:YAG LTK (2 ring treatment)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Noncontact Ho:YAG LTK
Number of subjects: 28
Study: 1493083

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3033444

Group type: EXPERIMENTAL
Intervention: Conjugated oestrogens (CE) 0.625 mg/day for 21 days + norethisterone (NET) 5 mg/day from day 12 to day 21
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: CE + cyproterone acetate (CPA) 12.5 mg/day from day 1 to day 10
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (EV) 2 mg/day for 21 days + NET
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: EV + CPA
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Oestriol (E3) 2‐4 mg/day
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Tibolone (ORG OD14) 2.5 mg/day
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo, one tablet/day
Number of subjects: 113
Study: 29340676

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (n=121)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (n=119)
Number of subjects: 240
Study: 26803560

Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional loading group
Number of subjects: 19
Study: 24965272

Group type: EXPERIMENTAL
Intervention: SonixGPS-guided PCNL
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional ultrasound-guided PCNL
Number of subjects: 88
Study: 23113955

Group type: EXPERIMENTAL
Intervention: Routine practice assessment and feedback
Number of subjects: 5227

Group type: EXPERIMENTAL
Intervention: Assessment-only without feedback
Number of subjects: 5227

Group type: COMPARATOR
Intervention: Neither assessment nor feedback
Number of subjects: 5227

Group type: EXPERIMENTAL
Intervention: Feedback intervention for risky drinkers
Number of subjects: 5227
Study: 20402565

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 18580254

Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 12
Study: 16098015

Group type: EXPERIMENTAL
Intervention: Extended genetic counselling (two sessions of education and reflection held 1 month apart)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Shortened genetic counselling (a single educational session)
Number of subjects: 26
Study: 12619423

Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Lidocaine pomade
Number of subjects: 62
Study: 10797866

Group type: EXPERIMENTAL
Intervention: SPE‐712‐1 oral suspension 300 mg/15 mL
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rotram tablets 300 mg
Number of subjects: 24
Study: 7720912

Group type: EXPERIMENTAL
Intervention: Oral micronized DHEA (50 mg/d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2116441

Group type: EXPERIMENTAL
Intervention: Calcium infusion started 1 min after TRH (Group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Calcium infusion started 10 min after TRH (Group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Calcium infusion started 20 min after TRH (Group C)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control study (no calcium infusion)
Number of subjects: 18
Study: 31938840

Group type: EXPERIMENTAL
Intervention: 4 cc autologous muscle-derived cell (AMDC) injections
Number of subjects: 58

Group type: COMPARATOR
Intervention: 4 cc placebo solution injections
Number of subjects: 58
Study: 30204685

Group type: EXPERIMENTAL
Intervention: Mozart's Symphony No. 40
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 208
Study: 26645209

Group type: EXPERIMENTAL
Intervention: Lurasidone (40-80 mg/d, flexibly dosed)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 25091659

Group type: EXPERIMENTAL
Intervention: Pertuzumab (in combination with trastuzumab and docetaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (trastuzumab plus docetaxel)
Number of subjects: 0
Study: 22069246

Group type: EXPERIMENTAL
Intervention: Concomitant inflammatory bowel disease (IBD)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No concomitant inflammatory bowel disease (Control group)
Number of subjects: 82
Study: 20182880

Group type: EXPERIMENTAL
Intervention: Two-staged ORIF
Number of subjects: 56

Group type: COMPARATOR
Intervention: Limited internal fixation with external fixator (LIFEF)
Number of subjects: 56
Study: 18801382

Group type: EXPERIMENTAL
Intervention: Sound intensity change
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 16158743

Group type: EXPERIMENTAL
Intervention: Kanefron H (KH) with phosphomycin (2 pellets 3 times a day for 30 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Kanefron H (KH) after initial anti-inflammatory treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (spasmolytic and anti-inflammatory therapy)
Number of subjects: 48
Study: 12665729

Group type: EXPERIMENTAL
Intervention: Computer-assisted instructional (CAI) game focusing on reducing environmental irritants/allergens and correct use of prescribed medications for 12 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 101
Study: 10757465

Group type: EXPERIMENTAL
Intervention: Imidapril (10 mg) administered in the morning (07:00)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imidapril (10 mg) administered in the evening (18:00)
Number of subjects: 20
Study: 8843225

Group type: EXPERIMENTAL
Intervention: Bivalent recombinant baculovirus influenza A vaccine (rHA0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monovalent recombinant baculovirus influenza A vaccine (rHA0)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard trivalent inactivated vaccine (TIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing doses of A/Texas rHA0 (15 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing doses of A/Texas rHA0 (45 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing doses of A/Texas rHA0 (135 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bivalent HA
Number of subjects: 0
Study: 1378478

Group type: EXPERIMENTAL
Intervention: Topical retinoic acid (RA) treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 5
Study: 6468776

Group type: EXPERIMENTAL
Intervention: High-pass filtered noise with cutoff frequency of 500 Hz
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-pass filtered noise with cutoff frequency of 1000 Hz
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High-pass filtered noise with cutoff frequency of 2000 Hz
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Wider band signals
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lower frequency signals
Number of subjects: 18
Study: 30882477

Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard oxygen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Noninvasive ventilation
Number of subjects: 30
Study: 30005270

Group type: EXPERIMENTAL
Intervention: High-value penalty
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Low-value penalty
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-value reward
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Low-value reward
Number of subjects: 78
Study: 26414418

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 593

Group type: COMPARATOR
Intervention: Control group (middle school as usual)
Number of subjects: 593
Study: 24472622

Group type: EXPERIMENTAL
Intervention: tDCS (2 mA) with anode over PZ and cathode over AF4 (P+F‐)
Number of subjects: 16

Group type: COMPARATOR
Intervention: tDCS (2 mA) with anode over AF4 and cathode over PZ (P‐F+)
Number of subjects: 16
Study: 22264426

Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) treatment
Number of subjects: 1823

Group type: COMPARATOR
Intervention: Standard care (not explicitly mentioned but implied as control)
Number of subjects: 1823
Study: 19129382

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 0
Study: 17088024

Group type: EXPERIMENTAL
Intervention: 40 mg cortisol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15734714

Group type: EXPERIMENTAL
Intervention: ASLF bread breakfast
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard white bread breakfast
Number of subjects: 11
Study: 12065562

Group type: EXPERIMENTAL
Intervention: Self-administered stress management training
Number of subjects: 411

Group type: COMPARATOR
Intervention: Professionally administered stress management training
Number of subjects: 411

Group type: COMPARATOR
Intervention: Usual psychosocial care only
Number of subjects: 411
Study: 9797599

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG with low osmolarity oral rehydration solution (224 mosmol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced osmolarity oral rehydration solution (224 mosmol/l)
Number of subjects: 0
Study: 7894828

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (HBV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control non vaccinated zone (NVZ)
Number of subjects: 0
Study: 2203243

Group type: EXPERIMENTAL
Intervention: Bepridil (200 mg/day twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CERM 4205 (200 mg/day twice daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 12
Study: 1009279

Group type: EXPERIMENTAL
Intervention: Blood pressure screening measurement
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Previous blood pressure measurement
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Hypertension control
Number of subjects: 85
Study: 31093796

Group type: EXPERIMENTAL
Intervention: Oral screen after MMF
Number of subjects: 60

Group type: COMPARATOR
Intervention: MMF only (Control)
Number of subjects: 60
Study: 28085793

Group type: EXPERIMENTAL
Intervention: Cord blood 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 939
Study: 25990454

Group type: EXPERIMENTAL
Intervention: High-fat non-dairy meal supplemented with milk (HFM meal)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-fat dairy meal (HFD meal)
Number of subjects: 19

Group type: COMPARATOR
Intervention: High-fat non-dairy control meal (HFC meal)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-fat meals (HFM, HFD, HFC)
Number of subjects: 19
Study: 23269772

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (second cycle)
Number of subjects: 12
Study: 21359235

Group type: EXPERIMENTAL
Intervention: Six-point acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Four-point acupuncture
Number of subjects: 20
Study: 19280523

Group type: EXPERIMENTAL
Intervention: Schisandra chinensis extract (SchE) 300 mg twice daily for 14 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 120 mg three times daily for 14 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Talinolol alone (control)
Number of subjects: 12
Study: 16906641

Group type: EXPERIMENTAL
Intervention: Miconazole 2% gel applied four times daily for 2 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zataria multiflora 0.1% gel applied four times daily for 2 weeks
Number of subjects: 24
Study: 12463384

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study: 10490157

Group type: EXPERIMENTAL
Intervention: High dose fentanyl (15 microg x kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low dose fentanyl (1 microg x kg(‐1))
Number of subjects: 60